Diabetic Renal-Retinal Syndrome : 21st Century Management Now

After a decade or longer, approximately one-third of individuals with either type 1 or type 2 diabetes commence a downhill course in which decreasing renal function and failing vision define a Renal-Retinal Syndrome, dominating all aspects of life and presaging early death. Only a generation ago, su...

Full description

Main Author: Friedman, Eli A.
Corporate Author: SpringerLink (Online service)
Other Authors: L’Esperance, Francis A. (Editor)
Format: eBook
Language:English
Published: Dordrecht Springer Netherlands 1998, 1998
Subjects:
Online Access:
Collection: Springer Book Archives -2004 - Collection details see MPG.ReNa
LEADER 03904nmm a2200349 u 4500
001 EB000718514
003 EBX01000000000000000571596
005 00000000000000.0
007 cr|||||||||||||||||||||
008 140122 ||| eng
020 |a 9789401149624 
100 1 |a Friedman, Eli A. 
245 0 0 |a Diabetic Renal-Retinal Syndrome  |h Elektronische Ressource  |b 21st Century Management Now  |c edited by Eli A. Friedman, Francis A. L’Esperance 
260 |a Dordrecht  |b Springer Netherlands  |c 1998, 1998 
300 |a XV, 284 p  |b online resource 
505 0 |a epidemiology, scope and impact -- 2. Stages of diabetic nephropathy -- 3. Mesangial expansion in diabetic nephropathy: functional and genetic considerations -- 4. Nephropathy in NIDDM — an update -- 5. Clinical imperatives in diabetic nephropathy: the devastating impact of comorbidity -- 6. Dialysis in diabetic patients: three decades of experience, from 1964 to 1997 -- 7. Hemodialysis in patients with diabetes mellitus -- 8. Continuous ambulatory peritoneal dialysis in 224 diabetics with end stage renal disease: evidence of improved survival over the past 10 years -- 9. The natural history and classification of diabetic retinopathy -- 10. Long-term visual outcome of diabetic patients treated with panretinal photocoagulation -- 11. A new hypothesis on mechanisms of retinal vascular permeability in diabetes -- 12. Angiogenesis in diabetic retinopathy: a history of accomplishment, discovery and promise -- 13. Surgical management of proliferative dia 
653 |a Medicine 
653 |a Diabetes 
653 |a Nephrology 
653 |a Ophthalmology 
653 |a Medicine & Public Health 
653 |a Nephrology 
653 |a Diabetes 
653 |a Ophthalmology 
700 1 |a L’Esperance, Francis A.  |e [editor] 
710 2 |a SpringerLink (Online service) 
041 0 7 |a eng  |2 ISO 639-2 
989 |b SBA  |a Springer Book Archives -2004 
856 |u http://dx.doi.org/10.1007/978-94-011-4962-4?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 616.61 
520 |a After a decade or longer, approximately one-third of individuals with either type 1 or type 2 diabetes commence a downhill course in which decreasing renal function and failing vision define a Renal-Retinal Syndrome, dominating all aspects of life and presaging early death. Only a generation ago, survival after onset of end-stage renal disease (ESRD) in diabetes was limited because rehabilitation was preempted by blindness, limb amputation, stroke, and heart disease. By 1998, however, team management has improved the outlook, with preserved sight and return to work and home responsibilities, usually for a decade or longer, following kidney transplantation and laser photocoagulation. Recognition of the critical requirement for blood pressure regulation and metabolic control are central themes in management. In this unique book, the accomplishments of ophthalmologists, nephrologists, diabetologists, transplant surgeons, and basic scientists are blended into a strategic approach that may be readily applied by all those caring for diabetic patients. Each of twenty-one presentations suitable for primary care physicians, as well as for subspecialists concerned with macrovascular and microvascular complications of diabetes, is placed in perspective by an introductory editorial analysis. Promising near-term innovative therapies, including insertion of genetically engineered beta cells or polymer-coated islets of Langerhans, interdiction of kinins that promote retinal angiogenesis, and prevention of synthesis of advanced glycosylated endproducts (AGEs), are presented in detail. While comprehensive care of diabetic patients reflects multiple incremental advances that in sum afford major benefit, this text envisions further remarkable changes likely to suppress and possibly entirely prevent the Diabetic Renal-Retinal Syndrome